Can a patient on dialysis safely take Januvia (sitagliptin), and what dose is recommended?

Januvia (Sitagliptin) in Dialysis Patients

Yes, Januvia is safe for dialysis patients at a reduced dose of 25 mg once daily, and can be taken without regard to the timing of hemodialysis. 1

Dosing Algorithm for Dialysis

The FDA-approved dosing for sitagliptin in patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis is straightforward:

• Standard dose (normal kidney function): 100 mg once daily
• Moderate renal insufficiency (CrCl 30-50 mL/min): 50 mg once daily
• Severe renal insufficiency (CrCl <30 mL/min) or ESRD on dialysis: 25 mg once daily 1

The medication can be administered at any time, independent of when dialysis occurs. 1

Guideline Support

Both the 2022 ADA/KDIGO consensus report and KDIGO clinical practice guidelines list DPP-4 inhibitors (including sitagliptin) as appropriate glucose-lowering agents for patients with type 2 diabetes and eGFR <30 mL/min per 1.73 m² or those treated with dialysis. 2, 3 The guidelines specifically note that sitagliptin requires dose reduction to a maximum of 25 mg once daily in stage 5 CKD (eGFR <15 mL/min per 1.73 m²). 2

Clinical Evidence

A 54-week randomized trial specifically evaluated sitagliptin 25 mg daily in 64 patients with type 2 diabetes and ESRD on dialysis. The study demonstrated:

• Efficacy: HbA1c reduction of -0.72% from baseline
• Safety: Lower incidence of symptomatic hypoglycemia (6.3%) compared to glipizide (10.8%)
• Severe hypoglycemia: 0% with sitagliptin versus 7.7% with glipizide 4

The medication was well-tolerated over the full study duration in dialysis patients. 4

Important Clinical Considerations

When to Reduce Insulin or Sulfonylurea Doses

If the patient is also taking insulin or a sulfonylurea, reduce those doses when starting sitagliptin to minimize hypoglycemia risk. 1 This is particularly important in dialysis patients who already have altered drug clearance.

Monitoring Requirements

• Assess renal function before initiating sitagliptin (though this is already established in dialysis patients)
• Monitor for signs of pancreatitis (abdominal pain, nausea, vomiting) and discontinue immediately if suspected 1
• Watch for hypersensitivity reactions, which can occur within the first 3 months 1

Common Pitfalls to Avoid

• Do not use the standard 100 mg dose in dialysis patients - this is the most critical error to avoid. The 25 mg dose is mandatory for ESRD. 1
• Do not adjust timing around dialysis sessions - unlike some medications, sitagliptin does not require coordination with dialysis schedules 1
• Do not use in type 1 diabetes or diabetic ketoacidosis - sitagliptin is ineffective in these settings 1

Advantages in Dialysis Population

Compared to sulfonylureas (another option for dialysis patients per guidelines 2, 3), sitagliptin offers:

• Significantly lower hypoglycemia risk 4, 5
• Weight neutrality or modest weight loss versus weight gain 5
• Once-daily dosing with no titration needed
• Can be taken with or without food 1